About the Company
We do not have any company description for Arcellx, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Arcellx, Inc.
Arcellx, Inc. Reports Increased Losses Amid Rising R&D Costs
Arcellx, Inc. ( ($ACLX) ) has released its Q2 earnings. Here is a breakdown of the information Arcellx, Inc. presented to its investors. Arcellx, ...
Optimizing Investment Decisions: Unveiling the Buy Rating for Arcellx Inc.
Arcellx Inc (ACLX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham maintained a Buy rating on the stock and has a ...
Arcellx, Inc. (ACLX) Stock Price, News, Quote & History - Yahoo Finance
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates Arcellx (ACLX) delivered earnings and revenue surprises of 11.11% and 26.06%, respectively, for the quarter ended September 2024.
Arcellx (ACLX) Surged in Q3. Here’s Why - Yahoo Finance
On October 31, 2024, Arcellx, Inc. (NASDAQ:ACLX) stock closed at $84.27 per share with a market capitalization of $4.53 billion.
4 Analysts Assess Arcellx: What You Need To Know
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
Positive Outlook for Arcellx Inc. Based on Promising Clinical Trial ...
Arcellx, Gilead announce new data from iMMagine-1 study of anitocabtagene autole Arcellx price target raised to $115 from $73 at Barclays Arcellx, Inc. Reports Q3 2024 Earnings Highlights ...
Arcellx Provides First Quarter 2024 Financial Results
About Arcellx, Inc. Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases.
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize ...
Arcellx, Inc. Forward-looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the ...
Arcellx Inc. | BioWorld
If there had been any lingering market concerns following the temporary partial clinical hold earlier this year for Arcellx Inc.’s multiple myeloma CAR T-cell therapy, CART-ddBCMA, they were likely ...
FDA Gives Green Signal To Arcellx's Stopped Blood Cancer Study
Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2026. Price Action: ACLX shares are down 0.09% at $33.66 premarket on the last check ...
Arcellx: The Gilead Deal Derisks And Proves Their Technology
Summary Arcellx, Inc. produced excellent data for their ddBCMA program. The data helped clinch a deal with Gilead. Arcellx goes up against Johnson & Johnson's formidable carvykti, but now it has help.
Pfenex and Arcellx Announce a Development, Evaluation and ... - Nasdaq
--Pfenex Inc. and Arcellx, Inc. today announced a Development, Evaluation and License agreement under which Arcellx gains access to the proprietary Pfenex Expression Technology ® platform to ...
Similar Companies
Loading the latest forecasts...